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Obesity caused by feeding of a high-fat diet (HFD) is associated with an increased activation of c-Jun
NH2-terminal kinase 1 (JNK1). Activated JNK1 is implicated in the mechanism of obesity-induced insulin
resistance and the development of metabolic syndrome and type 2 diabetes. Significantly, Jnk1/ mice are
protected against HFD-induced obesity and insulin resistance. Here we show that an ablation of the Jnk1 gene
in skeletal muscle does not influence HFD-induced obesity. However, muscle-specific JNK1-deficient (MKO)
mice exhibit improved insulin sensitivity compared with control wild-type (MWT) mice. Thus, insulin-stimu-
lated AKT activation is suppressed in muscle, liver, and adipose tissue of HFD-fed MWT mice but is suppressed
only in the liver and adipose tissue of MKO mice. These data demonstrate that JNK1 in muscle contributes to
peripheral insulin resistance in response to diet-induced obesity.
Obesity is a major risk factor for the development of insulin
resistance, hyperglycemia, and metabolic syndrome that can
lead to -cell dysfunction and type 2 diabetes (8). The preva-
lence of human obesity represents a serious health problem in
the United States. It is therefore important that we obtain a
detailed understanding of the molecular mechanism that ac-
counts for obesity-induced insulin resistance. Recent progress
has led to the identification of signal transduction pathways
that may mediate the effects of obesity on insulin resistance
(14, 23).
c-Jun NH2-terminal kinase 1 (JNK1) represents one signal-
ing pathway that has been implicated in the pathogenesis of
metabolic syndrome and type 2 diabetes (21). JNK1 is acti-
vated when mice are fed a high-fat diet (HFD) (7). Moreover,
Jnk1/ mice are protected against HFD-induced insulin re-
sistance (7). The mechanism of protection is mediated, in part,
by the failure of Jnk1/ mice to develop HFD-induced obesity
(7). However, JNK1 can regulate insulin resistance indepen-
dently of obesity. Thus, mice with an adipose tissue-specific
JNK1 deficiency develop normal diet-induced obesity but ex-
hibit selective protection against HFD-induced insulin resis-
tance in both the liver and adipose tissue (16). These data
indicate that adipose tissue JNK1 plays a critical role during
the development of HFD-induced insulin resistance.
The liver plays a key role in the insulin-stimulated dis-
posal of blood glucose during the postprandial state because
of reduced gluconeogenesis and increased glycogen synthe-
sis (17). However, glucose uptake by skeletal muscle also
makes a major contribution to insulin-stimulated glucose
disposal (17). Muscle may therefore be an important target
of obesity-induced JNK1 signaling and the regulation of
glucose homeostasis.
The purpose of this study was to test the role of JNK1 in
muscle. Our approach was to examine the effect of a muscle-
specific ablation of the Jnk1 gene in mice. We found that
HFD-fed control wild-type (MWT) mice and muscle-specific
JNK1-deficient (MKO) mice became similarly obese. However,
MKO mice were selectively protected against HFD-induced
insulin resistance. This analysis demonstrates that muscle
JNK1 contributes to the effects of obesity on insulin resistance.
MATERIALS AND METHODS
Mice. We previously described Jnk1/ mice (6) and Jnk1LoxP/LoxP mice (4).
Mck-Cre mice (3) were obtained from the Jackson Laboratories. The mice were
backcrossed to the C57BL/6J strain (Jackson Laboratories) and were housed in
facilities accredited by the American Association for Laboratory Animal Care.
The mice were genotyped by PCR analysis of genomic DNA (4). The animal
studies were approved by the Institutional Animal Care and Use Committee of
the University of Massachusetts Medical School.
RNA analysis. The expression of mRNA was examined by quantitative PCR
analysis using a 7500 Fast real-time PCR machine (Applied Biosystems).
TaqMan assays were used to quantitate Cd68 (Mm00839636_g1), C/ebp
(Mm00514283_s1), C/ebp (Mm00843434_s1), Cyp2e1 (Mm00491127_m1),
fatty acid synthase (Fas) (Mm00662322_g1), Icam1 (Mm00516023_m1), Ifn-
(Mm00801778_m1), Il6 (Mm00446190_m1), Il13 (Mm99999190_m1),
lysozyme (Lysz) (Mm00727183_m1), Lpl (Mm00434770_m1), microsomal
t r ig l ycer ide t rans fer prote in (Mttp ) (Mm00435015_m1), Pgc1
(Mm00447183_m1), and Tnfa (Mm00443258_m1) (Applied Biosystems). The
amounts of Il10 mRNA (CTGGACAACATACTGCTAACCG and GGGCAT
CACTTCTACCAGGTAA), Il12 mRNA (CCATTTTCCTTCTTGTGGAGCA
and AGACATGGAGTCATAGGCTCTG), Ppar mRNA (TGTGGGGATAA
AGCATCAGGC and CCGGCAGTTAAGATCACACCTA), Pgc1 mRNA (T
ACATGCATACCTACTGCCTGCCT and TTGGGCCAGAAGTTCCCTTAG
GAT), Srebp1 mRNA (GATGTGCGAACTGGACACCAG and CATAGGGG
GCGTCAAACAG), and Tgf1 mRNA (TGGTTTGCCATCGTTTTGCTG and
ACAGGTGAGGTTCACTGTTTCT) were examined by quantitative reverse
transcription (RT)-PCR using Sybr green detection. The relative mRNA expres-
sion was normalized by measurement of the amount of Gapdh mRNA
(4352339E) or 18S RNA (430449011032) in each sample using TaqMan assays
(Applied Biosystems).
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Medical School, 373 Plantation Street, Worcester, MA 01605. Phone:
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Immunoblot analysis. Tissue extracts were prepared by using Triton lysis
buffer (20 mM Tris [pH 7.4], 1% Triton X-100, 10% glycerol, 137 mM NaCl, 2
mM EDTA, 25 mM -glycerophosphate, 1 mM sodium orthovanadate, 1 mM
phenylmethylsulfonyl fluoride, and 10 g/ml of aprotinin and leupeptin). Ex-
tracts (20 to 50 g of protein) were examined by protein immunoblot analysis by
probing with antibodies to AKT, phospho-Thr308 AKT, and phospho-Ser473
AKT (Cell Signaling); IRS1 (16); phospho-Ser307 IRS1 (Millipore); and insulin
receptor  subunit, JNK1, and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (Santa Cruz). Immunocomplexes were detected by enhanced chemi-
luminescence (NEN). Quantitation of immunoblots was performed by using the
Odyssey infrared imaging system (Li-Cor Biosciences).
Measurement of glucose, adipokine, cytokine, and insulin concentrations in
blood. The blood glucose concentration was measured with an Ascensia Breeze
2 glucometer (Bayer). Concentrations of adipokines, cytokines, and insulin in
plasma were measured by enzyme-linked immunosorbent assay using a Luminex
200 machine (Millipore).
Glucose tolerance tests and ITTs. The mice were fed a standard chow diet or
a HFD (Iso Pro 3000 [Purina] and catalog number F3282 [Bioserve Inc.]) for 16
weeks. Glucose tolerance tests and insulin tolerance tests (ITTs) were performed
according to methods described previously (12).
Blood lipid analysis. Triglyceride was measured by using a kit purchased from
Sigma. Cholesterol was measured by using a Cardiocheck PA instrument (PTS,
Inc.). The concentration of free fatty acids was measured by using a kit purchased
from Roche. Fast-performance liquid chromatography analysis of serum lipopro-
teins was performed by the University of Cincinnati Mouse Metabolic Pheno-
typing Center (Lipid, Lipoprotein, and Glucose Metabolism Core; P. Tso, Di-
rector).
Measurement of hepatic triglyceride content. The hepatic triglyceride content
was measured using livers from mice fasted overnight. Total lipids were extracted
from liver samples (50 mg) by using an 8:1 mixture of chloroform and methanol
(4 h). The extracts were mixed with 1 N sulfuric acid and centrifuged (10 min).
The amount of triglyceride was measured by using a kit purchased from Sigma.
Protein kinase assays. JNK activity was measured by using an in vitro protein
kinase assay with c-Jun and [-32P]ATP as substrates (22).
Hyperinsulinemic-euglycemic clamp studies. The clamp studies were per-
formed at the University of Massachusetts Mouse Phenotyping Center. Briefly,
mice were fed a HFD diet (55% fat by calories; Harlan Teklad) or chow diet for
4 weeks, and whole body fat and lean mass were noninvasively measured by using
proton magnetic resonance spectroscopy (Echo Medical Systems). Following an
overnight fast, a 2-h assay using a hyperinsulinemic-euglycemic clamp was conducted
with conscious mice with a primed and continuous infusion of human insulin (prim-
ing with 150 mU/kg of body weight followed by 2.5 mU/kg/min) (Humulin; Eli Lilly),
and 20% glucose was infused at variable rates to maintain euglycemia (10). Whole-
body glucose turnover was assessed with a continuous infusion of [3-3H]glucose, and
2-deoxy-D-[1-14C]glucose (Perkin-Elmer) was administered as a bolus (10 Ci) at 75
min after the start of clamp studies to measure insulin-stimulated glucose uptake in
individual organs. At the end of use of the clamps, mice were anesthetized, and
tissues were taken for biochemical analysis (10).
Analysis of tissue sections. Histology was performed using tissue fixed in 10%
formalin for 24 h, dehydrated, and embedded in paraffin. Sections (7 m) were
cut and stained using hematoxylin and eosin (American Master Tech Scientific).
Immunohistochemistry was performed by staining tissue sections with an anti-
body to F4/80 (Abcam), a biotinylated secondary antibody (Biogenex), strepta-
vidin-conjugated horseradish peroxidase (Biogenex), and the substrate 3,3-
diaminobenzidene (Vector Laboratories), followed by brief counterstaining with
Mayer’s hematoxylin (Sigma).
Statistical analysis. Differences between groups were examined for statistical
significance using the Student test or analysis of variance with Fisher’s test.
RESULTS
To test the role of JNK1 in muscle, we created mice without
(MWT) and with (MKO) a selective defect in the expression of
JNK1 in muscle (Fig. 1A). Measurement of JNK activity dem-
onstrated that a HFD caused JNK activation in muscle, liver,
and adipose tissue of control (MWT) mice, but JNK activation
was detected only in liver and adipose tissue of MKO mice (Fig.
1B). Together, these data indicate that mice with a muscle-
specific JNK1 deficiency represent a model for the analysis of
muscle JNK1 deficiency.
Muscle-specific JNK1 deficiency does not affect diet-induced
obesity. It is established that HFD-fed Jnk1/ mice exhibit a
severe defect in the development of obesity (7). We therefore
tested whether a muscle-specific JNK1 deficiency might alter
HFD-induced obesity. Comparison of chow-fed and HFD-fed
MWT and MKO mice demonstrated that a muscle-specific JNK1
deficiency caused no defect in HFD-induced weight gain (Fig.
1C). Indeed, measurement of lean mass and fat mass by proton
magnetic resonance spectroscopy demonstrated no significant dif-
ferences between HFD-fed MKO and MWT mice (data not
shown). This analysis demonstrated that a muscle JNK1 defi-
ciency is not a major factor that contributes to the profound effect
of a whole-body JNK1 deficiency on the suppression of HFD-
induced obesity.
Feeding of an HFD caused hyperglycemia and hyperinsulin-
emia in mice, but no significant differences between MKO and
MWT mice were detected (Fig. 2D to F). Glucose tolerance
tests were performed to compare the responses of MKO and
MWT mice to a glucose challenge. We found that the HFD
caused glucose intolerance in both MKO and MWT mice (Fig.
2B). The HFD-induced glucose intolerance was caused, in
part, by decreased glucose-induced insulin release. No signifi-
cant differences between MKO and MWT mice were found in
studies of glucose-induced insulin release (Fig. 2C). These data
indicate that MKO and MWT mice mounted similar responses
to a glucose challenge.
JNK1 deficiency in muscle did not affect the blood concen-
tration of the adipokines leptin and resistin (Fig. 2G and H).
However, analysis of the concentration of cytokines in the
blood did indicate differences between MKO and MWT mice.
Thus, the blood concentrations of the inflammatory cytokines
tumor necrosis alpha (TNF-), gamma interferon (IFN-), and
interleukin-12 (IL-12) were greater in MKO mice than in MWT
mice (Fig. 2I, J, and L). In contrast, no significant difference in
the concentrations of the anti-inflammatory cytokine IL-10 in
the blood was detected between MKO and MWT mice (Fig. 2K).
JNK1 deficiency causes increased insulin signaling in mus-
cle. The insulin receptor substrate IRS-1 can be negatively
regulated by the JNK-mediated phosphorylation of IRS-1 on
Ser307 (1). We therefore anticipated that a loss of JNK1 in
muscle would attenuate the negative regulatory phosphoryla-
tion of IRS-1 on Ser307 and increase the insulin-stimulated
tyrosine phosphorylation of IRS-1. To test this hypothesis, we
examined the effect of insulin treatment of MWT and MKO
mice on insulin receptor and IRS-1 phosphorylation in muscle.
We found that the JNK1 deficiency did not affect insulin re-
ceptor tyrosine phosphorylation or the amount of expression of
the insulin receptor or IRS-1. However, the loss of JNK1 in
muscle reduced the inhibitory phosphorylation of IRS-1 on
Ser307 and increased the insulin-stimulated tyrosine phosphor-
ylation of IRS-1 (Fig. 1D). These data suggest that JNK1 plays
an important role in the regulation of IRS-1 and, therefore,
insulin signal transduction in muscle.
Mice with a muscle-specific JNK1 deficiency exhibit in-
creased insulin sensitivity. We performed an ITT to examine
whether MKO mice exhibit increased insulin sensitivity in vivo
compared with MWT mice (Fig. 2A). No significant differences
between MKO and MWT mice were detected when these mice
were fed a chow diet. In contrast, the HFD markedly suppressed
the ITT response in MWT mice, but HFD-fed MKO mice re-
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mained insulin sensitive (Fig. 2A). These data suggest that MKO
mice exhibit protection against HFD-induced insulin resistance.
To confirm the conclusion that MKO mice are more insu-
lin sensitive, we conducted a hyperinsulinemic-euglycemic
clamp study with conscious mice following 4 weeks of feed-
ing of a HFD or chow diet. The level of insulin-stimulated
whole-body glucose turnover was modestly but significantly
elevated in MKO mice compared with MWT mice following
feeding of a chow diet or HFD (Fig. 3A). Whole-body gly-
colysis rates tended to be higher in chow-fed MKO mice than
in chow-fed MWT mice (P  0.057), but whole-body glyco-
gen plus lipid synthesis rates were not altered in MKO mice
(Fig. 3B and C). No statistically significant differences in
basal or clamp glucose concentrations (data not shown),
hepatic glucose production (HGP) at the basal state or
during the insulin-stimulated (clamp) state, and hepatic in-
sulin action were detected between MKO and MWT mice
(Fig. 3D to F). The level of insulin-stimulated muscle glu-
cose uptake was significantly reduced in HFD-fed MWT mice
compared with chow-fed MWT mice, but muscle glucose
uptake in HFD-fed MKO mice was similar to that of chow-
fed MKO mice (Fig. 3G). In contrast, the HFD caused a
similar decrease in levels of insulin-stimulated glucose up-
take by adipose tissue in MKO and MWT mice (Fig. 3H).
These data demonstrate that MKO mice exhibit a selective
increase in skeletal muscle insulin sensitivity.
To obtain biochemical evidence for peripheral insulin
sensitivity, we examined insulin-stimulated AKT activation
in muscle, liver, and adipose tissue of MKO and MWT mice
(Fig. 4). Insulin treatment of chow-fed MKO and MWT mice
caused increased AKT activation. Feeding of an HFD sup-
pressed insulin-stimulated AKT activation in the liver and
adipose tissue of both MKO and MWT mice (Fig. 4B and C).
In contrast, the HFD suppressed insulin-stimulated AKT
FIG. 1. Creation of mice with muscle-specific JNK1 deficiency. (A) Extracts prepared from epididymal fat (white adipose tissue), liver, and
muscle (gastrocnemius, quadriceps, and soleus) of Mck-Cre Jnk1/ (MWT) mice and Mck-Cre Jnk1LoxP/LoxP (MKO) mice were examined by
immunoblot analysis by probing with antibodies to JNK1 and GAPDH. (B) MWT and MKO mice were fed a chow diet (ND) or HFD (HF) for 16
weeks and then fasted overnight. JNK protein activity in epididymal fat (adipose tissue), liver, and muscle was measured in a protein kinase (KA)
assay using c-Jun and [-32P]ATP as substrates. The cell extracts used for the protein kinase assay were also examined by immunoblot analysis by
probing with antibodies to JNK1 and GAPDH. (C) Male MWT and MKO mice (8 to 10 weeks old) were fed either a chow diet (ND) or HFD for
16 weeks. The body weight of the mice was measured (means 	 standard deviations [SD]) (n  10). No significant difference between the body
weights of MWT and MKO mice was detected (P 
 0.05). (D) Chow-fed MWT and MKO mice were fasted overnight and then treated by
intraperitoneal injection of 1.5 mU/kg insulin. Extracts prepared from gastrocnemius muscle at 10 min postinjection were examined by immunoblot
analysis using antibodies to the insulin receptor (IR), IRS-1, phospho-Tyr, and IRS-1-Ser307. IP, immunoprecipitation.
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activation in muscle of MWT mice but not MKO mice (Fig.
4A). These data support the conclusion that MKO mice
exhibit a selective rescue from HFD-induced skeletal muscle
insulin resistance.
Systemic effects of muscle-specific JNK1 deficiency. The ab-
lation of the Jnk1 gene in muscle may lead to changes in other
tissues. Indeed, a comparison of the livers of MWT and MKO
mice demonstrated that a muscle JNK1 deficiency caused in-
FIG. 2. Effect of muscle-specific JNK1 deficiency on diet-induced obesity. (A) ITTs of MWT and MKO male mice fed either a chow diet (ND) or an
HFD for 16 weeks were performed by intraperitoneal injection of insulin (1.5 U/kg body mass). The concentration of blood glucose was measured
(means 	 SD) (n 10). Statistically significant differences between MKO and MWT are indicated (*, P 0.05). (B) Glucose tolerance tests (GTT) with
chow-fed (ND) and HFD-fed MWT and MKO mice were performed by measurement of blood glucose concentrations in animals following intraperitoneal
injection of glucose (1 g/kg). The data presented represent the means 	 SD (n  10 to 15). No statistically significant differences between MWT and
MKO mice were detected (P
 0.05). (C) Glucose-induced insulin release. The effect of the administration of glucose (2 g/kg body mass) by intraperitoneal
injection on blood insulin concentrations was examined (means 	 SD) (n  13 to 15). No statistically significant differences between MWT and MKO
mice were detected (P 
 0.05). (D and E) Chow-fed and HFD-fed (HF) MWT and MKO mice were fasted overnight (D) or fed ad libitum (E), and the
blood glucose concentration was measured (mean	 SD) (n 10 to15). No statistically significant differences were detected (P
 0.05). (F to L). The
concentrations of insulin, adipokines, and cytokines in blood of chow-fed (ND) and HFD-fed (HF) MWT and MKO mice fasted overnight were measured
by enzyme-linked immunosorbent assay (means 	 SD) (n  10 to 15). Statistically significant differences are indicated (*, P  0.05).
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creased hepatic steatosis (Fig. 5A). Measurements of hepatic
triglyceride accumulation demonstrated increased amounts of
triglyceride in both chow-fed and HFD-fed MKO mice com-
pared with MWT mice (Fig. 5B). The increased level of hepatic
triglyceride accumulation was not accounted for by increased
levels of expression of a lipogenic transcription factor/coacti-
vator (e.g., Srebp1, C/ebp, C/ebp, and Pgc1) or lipogenic
genes (e.g., Fas) (Fig. 6). However, the triglyceride accumula-
tion in MKO mice may account for the increased levels of
expression of Tnf mRNA that were detected in the livers of
MKO mice compared to MWT mice (Fig. 7).
The increased accumulation of hepatic triglyceride was associ-
ated with increased amounts of triglyceride in the blood of MKO
mice compared with MWT mice (Fig. 8A). Triglyceride in the liver
is exported to the blood in the form of serum lipoprotein (very-
low-density lipoprotein [VLDL]). No significant difference in the
levels of expression of microsomal triglyceride transport protein
Mttp mRNA in the livers of MKO and MWT mice was detected
(Fig. 6). However, increased amounts of VLDL triglyceride and
decreased amounts of low-density lipoprotein and high-density
lipoprotein cholesterol were found in the blood of MKO mice
compared with MWT mice (Fig. 8B). This increased amount of
VLDL triglyceride might result from decreased triglyceride hy-
drolysis by lipoprotein lipase (LPL). Indeed, muscle LPL is a
major contributor to VLDL triglyceride hydrolysis in vivo (19),
and muscle-specific Lpl knockout mice exhibit increased levels of
VLDL triglyceride in blood and a redistribution of triglyceride to
nonmuscle tissues within the body (20). Quantitative RT-PCR
analysis demonstrated that Lpl mRNA expression in the quadri-
ceps muscle of MKO mice was reduced by 60%	 16% compared
with MWT mice (mean 	 standard error) (n  5; P  0.05), but
no significant difference in Lpl mRNA expression levels in adi-
pose tissues of MWT and MWT mice was detected (n  5; P 

0.05). This decrease in levels of LPL expression in muscle may
contribute to the increased amount of triglyceride detected in the
blood and the liver of MKO mice.
It is likely that the increased amount of triglyceride in the
blood of MKO mice may affect other tissues. To test this hy-
pothesis, we compared adipose tissues of MKO and MWT mice.
This analysis demonstrated that the muscle-specific JNK1 de-
ficiency increased the HFD-induced infiltration of adipose tis-
sue by myeloid cells (Fig. 9). Morphological analysis and immu-
nohistochemical analysis of adipose tissue sections demonstrated
increased numbers of F4/80-positive myeloid cells in HFD-fed
MKO mice compared with MWT mice (Fig. 9A). Quantitative
RT-PCR analysis of gene expression confirmed increased lev-
els of expression of the myeloid marker genes Lyzs and Cd68
(Fig. 9B). Increased levels of expression of Icam1 and the
cytokines Il6, Il12, and Il13 (but not Il-10, Tnf, or Tgf1) were
also detected in the adipose tissue of MKO mice compared with
MWT mice (Fig. 9B). It was previously established that IL-13
expressed by adipocytes plays a key role in the activation of
macrophages by the alternate M2a pathway (mediated by per-
oxisome proliferator-activated receptor / [PPAR/]) that
influences insulin sensitivity (5). Together, these data indicate
that the muscle-specific JNK1 deficiency caused an increased
inflammatory response in adipose tissue. It is possible that this
response is mediated by the increased amount of triglyceride in
the blood of MKO mice compared with that in the blood of
MWT mice.
DISCUSSION
JNK1 is implicated in obesity-induced insulin resistance,
metabolic syndrome, and type 2 diabetes. Thus, the treatment
of mice with a JNK inhibitor decreases the concentration of
FIG. 3. Effect of muscle-specific deficiency of JNK1 on insulin sensitivity. (A to F) Insulin sensitivity was measured using a hyperinsulinemic-
euglycemic clamp with conscious chow-fed (ND) and HFD-fed (HF) MKO and MWT mice. (A) Insulin-stimulated whole-body glucose turnover.
(B) Whole-body glycolysis. (C) Whole-body glycogen plus lipid synthesis. (D) Basal HGP. (E) Insulin-stimulated rate of HGP during the clamp assay.
(F) Hepatic insulin action expressed as the insulin-mediated percent suppression of basal HGP. The data presented are the means	 standard errors for
approximately six to nine experiments. Statistically significant differences between MKO mice and MWT mice are indicated (*, P  0.05). (G and H)
Glucose uptake in white adipose tissue (G) and gastrocnemius muscle (H) was measured in the hyperinsulinemic-euglycemic clamp study. The data are
expressed as the percent suppression of glucose uptake caused by feeding of an HFD and presented as the means 	 standard errors for approximately
four to nine experiments. Statistically significant differences between MKO mice and MWT mice are indicated (*, P  0.05).
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glucose in blood and improves insulin sensitivity (2, 9, 18).
Moreover, Jnk1/ mice are protected against HFD-induced
insulin resistance (7). However, the analysis of Jnk1/ mice is
complicated because these mice fail to develop HFD-induced
obesity (7). The effect of the JNK1 deficiency to protect against
insulin resistance may therefore be a secondary consequence
of the failure to become obese. However, recent studies using
tissue-specific Jnk1 knockout mice have provided important
insights into this question. The selective ablation of the Jnk1
gene in adipose tissue (16), liver (15), or muscle (this study) did
not affect HFD-induced obesity. Nevertheless, HFD-fed mice
with a selective deficiency of JNK1 in adipose tissue or muscle
exhibit improved insulin sensitivity compared with control
mice. These data strongly support the conclusion that JNK1 is
important for the normal development of HFD-induced insu-
lin resistance.
The regulation of insulin resistance by JNK1 is incompletely
understood. It is likely that JNK1 functions are mediated by
more than one mechanism. Thus, JNK1-dependent cytokine
expression can contribute to inflammation-associated insulin
resistance in HFD-fed mice (16). This mechanism enables
JNK1 in one tissue to regulate insulin resistance in other tis-
sues; for example, JNK1-dependent IL-6 expression by adipose
tissue can mediate hepatic insulin resistance (16). JNK1 may
also function by a more direct mechanism by inhibiting insulin
signal transduction. One example is represented by the phos-
phorylation of the adapter protein IRS-1 on the negative reg-
ulatory site Ser307 that prevents the interaction of IRS-1 with
the insulin receptor (1, 11). This mechanism may be important
for the improved insulin sensitivity of adipose tissue in HFD-
fed mice with an adipose-specific JNK1 deficiency (16). This
conclusion is consistent with the previously reported finding
that Jnk1 gene ablation in adipose tissue suppressed IRS-1
phosphorylation on Ser307 (16). Similarly, the muscle-specific
JNK1 deficiency decreased IRS-1 phosphorylation on Ser307
and improved insulin sensitivity. Indeed, the muscle-specific
FIG. 4. Effect of muscle-specific JNK1 deficiency on insulin-stimulated AKT activation. Chow-fed (ND) and HFD-fed (HF) MWT and MKO
mice were fasted overnight and treated by intraperitoneal injection of insulin (1.5 U/kg body mass). Extracts prepared from gastrocnemius muscle
(A), liver (B), and epididymal adipose tissue (C) at 10 min postinjection were examined by immunoblot analysis with antibodies to JNK1, AKT,
phospho-AKT, and GAPDH.
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JNK1 deficiency protected insulin-stimulated AKT activation
selectively in muscle, but not liver or adipose tissue, after
feeding of an HFD. This observation suggests that JNK1 in
muscle can regulate insulin resistance by a cell-autonomous
mechanism that involves, at least in part, the negative regula-
tory phosphorylation of IRS-1. This conclusion is consistent
with the results of a recently reported study that demonstrated
an improved insulin sensitivity of transgenic mice that ex-
pressed a phosphorylation-defective IRS-1 protein in muscle
(13).
One unexpected consequence of the muscle-specific JNK1
deficiency was the finding that the triglyceride concentration in
blood of MKO mice was greater than that in blood of MWT
mice. The mechanism that accounts for the increase in the
concentration of triglyceride in blood is unclear. However, a
reduced level of expression of muscle LPL may represent one
contributing factor. It was previously established that muscle
LPL acts to hydrolyze VLDL triglyceride (19). A recent report
demonstrated that a muscle-specific LPL deficiency caused an
increase in blood triglyceride concentrations and the redistri-
bution of triglyceride to nonmuscle tissues within the body
(20). A consequence of the redistribution of triglyceride in
these LPL-deficient mice is an increased insulin sensitivity in
muscle but a decreased insulin sensitivity in other tissues, in-
cluding liver and adipose tissue (20). These data suggest that
the redistribution of triglyceride may contribute to the pheno-
type of muscle-specific JNK1-deficient mice and that reduced
muscle LPL expression levels may represent one factor that
mediates the increased muscle insulin sensitivity of HFD-fed
MKO mice. However, unlike chow-fed muscle-specific-LPL-
deficient mice, chow-fed MKO mice did not exhibit decreased
insulin sensitivity in muscle and adipose tissue; this is most
likely because the reduction in muscle LPL expression levels in
MKO mice differs from the complete absence of muscle LPL in
LPL-deficient mice. Nonetheless, the reduced level of LPL
expression in muscle of MKO mice may contribute to the in-
creased triglyceride accumulation in blood and liver and in-
FIG. 5. Muscle-specific JNK1 deficiency causes increased diet-in-
duced hepatic steatosis. (A) Chow-fed (ND) and HFD-fed (HF) MWT
and MKO mice were fasted overnight. Representative sections of the
liver stained with hematoxylin and eosin are presented. Scale bar, 100
m. (B) The amount of hepatic triglyceride was measured in mice
fasted overnight (means 	 SD) (n  10). Statistically significant dif-
ferences between MKO and MWT are indicated (*, P  0.05; **, P 
0.01).
FIG. 6. Effect of muscle-specific JNK1 deficiency on hepatic lipo-
genic gene expression. Gene expression in the liver of chow-fed (ND)
and HFD-fed (HF) MWT and MKO mice was measured by quantitative
RT-PCR analysis of mRNA. Data for the expression of transcription
factors (C/ebp, C/ebp, Ppar, and Srebp1), coactivators (Pgc1 and
Pgc1), fatty acid synthase (Fas), and microsomal triglyceride transfer
protein (Mttp) mRNA are presented. The relative mRNA expression
level was calculated by normalization of the data to the amount of 18S
RNA in each sample (means 	 SD) (n  6 to 8). Statistically
significant differences are indicated (*, P  0.05).
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creased inflammation of adipose tissue, particularly in HFD-
fed mice.
Together, the results of this study provide insight into the
mechanism of JNK1-mediated insulin resistance. These data
indicate that the protection of Jnk1/ mice against the effects
of feeding an HFD represents a complex phenotype that is
derived from effects of JNK1 in multiple tissues. The protec-
tion against HFD-induced obesity observed in studies of
FIG. 7. Effect of muscle-specific JNK1 deficiency on hepatic inflammatory gene expression. Gene expression in the liver of chow-fed (ND) and
HFD-fed (HF) MWT and MKO mice fasted overnight was measured by quantitative RT-PCR analysis of mRNA (TaqMan assays). Data for the
expression of Tnf, Il6, Ifn, Cd68, Icam1, Lyzs, and cytochrome p450 2E1 (Cye2e1) mRNAs are presented. The relative mRNA expression level
was calculated by normalization of the data to the amount of 18S RNA in each sample (means 	 SD) (n  6 to 8). Statistically significant
differences are indicated (*, P  0.05; **, P  0.01).
FIG. 8. Effect of muscle-specific JNK1 deficiency on blood lipids. (A) HFD-fed MWT and MKO mice were fasted overnight. The amounts of cholesterol,
triglyceride, and free fatty acid (FFA) in the blood were measured (means 	 SD) (n  10). Statistically significant differences between MKO and MWT are
indicated (*,P 0.05). (B) Analysis of VLDL, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) in the sera of HFD-fed M
WT and MKO mice.
Fast-performance liquid chromatography profiles of cholesterol (top) and triglyceride (bottom) are presented (means 	 SD) (n  10).
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FIG. 9. Muscle-specific JNK1 deficiency causes increased diet-induced inflammation of adipose tissue. (A) Chow-fed (ND) and HFD-fed (HF)
MWT and MKO mice were fasted overnight. Representative histological sections of epididymal adipose tissue stained with hematoxylin and eosin
(left panels) and with an antibody (F4/80) to a macrophage marker (right panels) are presented. Scale bar, 100 m. (B) Gene expression in
epididymal adipose tissue was measured by quantitative RT-PCR analysis of mRNA. The relative mRNA expression level was calculated by
normalization of the data to the amount of Gapdh mRNA in each sample (means 	 SD) (n  6 to 8). Statistically significant differences are
indicated (*, P  0.05; **, P  0.01).
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Jnk1/ mice is not accounted for by a JNK1 deficiency in
adipose tissue (16), liver (15), or muscle (this study). JNK1 in
adipose tissue is required for HFD-induced insulin resistance
in adipose tissue and liver (16). However, JNK1 in liver is not
required for HFD-induced hepatic insulin resistance (15).
Here we demonstrate that JNK1 in muscle is required for
HFD-induced muscle insulin resistance. This analysis indicates
that the overall phenotype of Jnk1/ mice represents a com-
plicated mixture of separate phenotypes caused by a JNK1
deficiency in different tissues.
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